Sangamo Therapeutics Announces Presentation At The 2018 Jefferies Global Healthcare Conference

On May 30, 2018 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) reported that management will present a corporate overview at the 2018 Jefferies Global Healthcare Conference in New York City (Press release, Sangamo Therapeutics, MAY 30, 2018, View Source [SID1234526968]). The presentation is scheduled for Wednesday, June 6th at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be archived on the Sangamo website following the event.

Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018

On May 30, 2018 Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, reported that CFO and Head of Corporate Strategy John Leaman, M.D., will present at the Jefferies Global Healthcare Conference in New York City at 10:30 a.m. ET on Wednesday, June 06, 2018 (Press release, Selecta Biosciences, MAY 30, 2018, View Source [SID1234527006]). A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Helix BioPharma Corp. Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

On May 30, 2018 Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that the Safety Review Committee ("SRC") reviewed safety data from the third dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of patients into the fourth dosing cohort (Press release, Helix BioPharma, MAY 30, 2018, http://www.helixbiopharma.com/helix-biopharma-corp-completes-third-dosing-cohort-initiates-enrollment-next-cohort-u-s-combination-treatment-study-lung-cancer-drug-candidate-l-dos47/ [SID1234527251]). LDOS001 is a dose escalation study of L-DOS47 with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer. Patients enrolled in the fourth dosing cohort will receive the next L-DOS47 dose level which is 3.0 micrograms of L-DOS47 per kilogram of patient body weight.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very encouraged that L-DOS47 in combination with chemotherapeutics continues to be safe and well tolerated by patients," said Heman Chao, Helix’s Chief Executive Officer. "We look forward to completing this trial under an FDA approved amendment to accelerate dose escalation for this trial".

The following is an update regarding the LDOS001 trial:

 No dose limiting toxicities reported at doses up to 1.5 µg/kg (cohort 3)

 From imaging data available on the first nine patients, four confirmed partial response have been observed with one patient achieving a tumor volume reduction of 91%
 Eight additional patients to complete the study if no dose limiting toxicity is observed or cohort expansion is required due to safety concern

Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention

On May 30, 2018 Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported it will present at the 8th Annual LD Micro Invitational Conference in Bel-Air, CA being held June 4-6, 2018 (Press release, Navidea Biopharmaceuticals, MAY 30, 2018, View Source [SID1234526950]). Jed Latkin, Chief Financial and Operating Officer of Navidea, will be giving a corporate presentation focused on Navidea’s clinical programs. In additional, Michael Goldberg, M.D., Chief Executive Officer of Navidea, along with other members of management will attend the 2018 BIO International Convention in Boston, MA being held June 4-7, 2018 to participate in meetings with potential clinical and commercial partners, investors, and other parties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: 8th Annual LD Micro Invitational
Presentation Date: Monday, June 4, 2018
Presentation Time: 1:00pm PT
Location: Luxe Sunset, Bel-Air, CA

The presentation at the LD Micro Invitational Conference will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.

The LD Micro Invitational Conference is one of the nation’s largest independent conferences for small/micro-cap companies, with more than 230 names presenting to 1,000+ attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

To schedule a meeting with Navidea management at either conference, please contact Navidea Investor Relations at [email protected].

About BIO:

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization’s bi-weekly email newsletter.

About LD Micro:

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

Affimed to Present at the Jefferies Global Healthcare Conference

On May 30, 2018 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported that Dr. Adi Hoess, CEO, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at 4:30 pm ET (Press release, Affimed, MAY 30, 2018, View Source [SID1234526969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.